Tg Therapeutics (TGTX) Cash & Equivalents (2011 - 2026)

Tg Therapeutics' Cash & Equivalents history runs 16 years deep, the most recent figure standing at $2.9 million for Q1 2026.

• On a quarterly basis, Cash & Equivalents fell 97.84% year-over-year to $2.9 million in Q1 2026; TTM through Mar 2026 was $2.9 million, a 97.84% decrease from a year earlier, with the FY2025 full-year figure at $1.3 million, up 256.6% from the prior year.
• Cash & Equivalents rose to $2.9 million in Q1 2026 per TGTX's latest filing, from $1.3 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $195.8 million in Q3 2024 and bottomed at $371000.0 in Q4 2024.
• The 5-year median for Cash & Equivalents is $102.3 million (2022), against an average of $102.7 million.
• Across the five-year window, Cash & Equivalents plunged 99.6% in 2024 and jumped 256.6% in 2025, its largest moves.
• Year by year, Cash & Equivalents stood at $102.3 million in 2022, then slipped by 9.16% to $92.9 million in 2023, then plunged by 99.6% to $371000.0 in 2024, then soared by 256.6% to $1.3 million in 2025, then surged by 116.02% to $2.9 million in 2026.
• Per Business Quant, the three latest TGTX Cash & Equivalents figures stand at $2.9 million (Q1 2026), $1.3 million (Q4 2025), and $178.3 million (Q3 2025).